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Abstract
Monahan, Christopher James. Ph.D. The University of Memphis. August 2013. A
Prospective Evaluation of PTSD Symptoms Following CPAP Treatment for SleepDisordered Breathing. Major Professor: Meghan E. McDevitt-Murphy, Ph.D.
Previous research has observed elevated rates of OSA observed in individuals
with PTSD compared to the general population. Retrospective studies suggest that
successful treatment of OSA in individuals with PTSD is related to reductions in
nightmares and overall PTSD symptom severity. The purpose of the current study was to
extend this research by prospectively examining PTSD sympomatology in a sample of
Veterans initiating treatment for OSA. Participants were 47 Veterans presenting to a
VAMC Neurology Sleep Clinic for overnight polysomnography. Veterans were eligible
if they were: (a) diagnosed with OSA; (b) received continuous positive airway pressure
(CPAP) treatment; and (c) had a minimum score of 25 on the baseline administration of
the PCL. The majority of the sample were male (n = 42; 89.4%) and Caucasian (n = 23;
48.9%) or African American (n = 22; 46.8%), with a mean age of 53.5 years. Veterans
completed self-report questionnaires across two pre-treatment and two post-treatment
(two weeks and four weeks from treatment initiation) time points. A 2 (treatment
compliance status) x 4 (time) mixed model repeated measures analysis was conducted on
PTSD symptom severity as measured by the PCL administered at each time point. A
statistically significant compliance status x time interaction emerged, (F(3, 102.15) =
5.66. p = .001) such that CPAP-compliant Veterans reported a statistically significant
reduction in PTSD symptoms from pre to post-treatment, whereas CPAP non-compliant
Veterans did not. These findings suggest that successful treatment of a physical sleep
disorder like OSA is associated with a subsequent reduction of posttraumatic distress.
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A Prospective Evaluation of PTSD Symptoms Following CPAP Treatment for SleepDisordered Breathing in Veterans
The diagnosis of posttraumatic stress disorder (PTSD) denotes psychological
symptoms across three broad domains: re-experiencing, avoidance/numbing, and
hyperarousal (DSM-IV-TR; APA, 2000). Although not unique to PTSD, sleep problems
are a salient aspect of this diagnosis and are characterized by persistent nightmares as
well as onset and/or maintenance insomnia (Ross, Ball, Sullivan, & Caroff, 1989). These
sleep-related symptoms are conceptualized as distinct from each other, whereby the
occurrence of nightmares (“recurrent distressing dreams”) is designated as a reexperiencing symptom and sleep initiation/maintenance difficulties reflect hyperarousal
(APA, 2000). Individuals with PTSD frequently report sleep initiation difficulties,
frequent mid-sleep awakenings, awakenings accompanied by panic or startle, and
nightmares (Harvey, Jones, Schimdt, 2003; Mellman, Kulick-Bell, Ashlock, & Nolan,
1995).
Although sleep disturbance in the context of PTSD may occur as a symptom of
the disorder, it may also occur as an independent phenomenon, in some cases pre-dating
other PTSD symptoms. And the relationship between PTSD and dysfunctional sleep
processes appears to be reciprocal. It is well documented that individuals with PTSD are
at elevated risk for sleep disturbance (see reviews: Germain, 2009; Harvey et al., 2003;
Maher, Rego, & Asnis, 2006; Pillar, Malhotra, & Lavie, 2000) with the severity of
disturbed sleep directly proportional to the level of PTSD symptom severity (Germain,
Buysse, Shear, Fayyad, & Austin, 2004; Krakow et al., 2001). A large majority (70-91%)
of individuals with PTSD report some sleep-related dysfunction (Maher et al., 2006).
Disturbed sleep following a traumatic experience has been found to predict future PTSD
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onset (Koren, Arnon, Lavie, & Klein, 2002) and is associated with more severe PTSD
symptomatology overall (Krakow et al., 2004; Lavie, 2006; Maher et al., 2006). It
appears then that sleep dysfunction can manifest as both an antecedent to and a
consequence of PTSD; however, the majority of extant research has focused on sleep
disturbance as a result of PTSD.
Despite extensive research on sleep disturbance and PTSD, one factor that has
received little attention in the literature to date is the co-occurrence of sleep-disorder
breathing (SDB) in individuals with PTSD. The SDB label has been used to refer to a
group of organic sleep disorders which cause a repetitive disruption to the respiratory
process during sleep. Relative to the general population, individuals with PTSD seem to
be at higher risk for SDB (Bixler et al., 2001; Maher et al., 2006). Unfortunately, few
studies that have examined sleep-related difficulties in individuals with PTSD have
concurrently examined SDB as a possible antecedent (Pillar et al., 2000). Interestingly,
retrospective studies suggest that successful treatment of SBD in individuals with PTSD
is associated with an improvement in nightmares and overall PTSD symptoms (Krakow
et al., 2000; Youakim, Doghramji, Schutte, 1998); however no studies have examined
prospectively whether changes in PTSD symptomatology occur following successful
treatment of SDB.
Disturbed Sleep and PTSD
As previously noted, higher rates of self-reported sleep disturbance have been
well-documented among individuals with PTSD compared to those without. Sleep
problems have been observed in a number of studies of individuals diagnosed with PTSD
including combat veterans (Inman, Silver, & Doghramji, 1990; Neylan et al., 1998),
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sexual assault survivors (Foa, Riggs, & Gershuny, 1995), motor vehicle accident (MVA)
survivors (Harvey & Bryant, 1998; Koren, Arnon, Lavie, & Ehud, 2002), and survivors
of natural disaster (Mellman et al., 1995; Sharan, Chaudhary, Kavathekar, & Saxena,
1996). Although many studies have employed self-report methods to assess sleep
disturbance, the gold standard for measuring sleep processes and diagnosing sleep
disorders is polysomnography (PSG). PSG uses psychophysiological instruments to
measure brain activity during sleep. PSG provides objective data regarding sleep episode
characteristics such as total sleep time, number of awakenings, and time spent in the
various stages. Although self-report studies have overwhelmingly suggested that PTSD is
associated with various sleep-related disturbances, studies that have used PSG to examine
sleep processes in PTSD have been less consistent in their findings (Breslau et al., 2004;
Klein, Koren, Arnon, & Lavie, 2002). In fact, the majority of studies using PSG have not
found a statistically significant difference in the rates of sleep disturbances for individuals
with PTSD compared to those without (Breslau et al., 2004; Fuller, Waters, & Scott,
1994; Klein, Koren, Arnon, & Lavie; 2002; Lavie, Katz, Pillar, & Zinger, 1998;
Mellman, Bustamante, Fins, Pigeon, & Nolan, 2002; Mellman, David, Kulick-Bell,
Hebding, & Nolan, 1995; Neylan et al., 2003; & Otte et al., 2007).
Despite the apparent lack of congruence among studies using objective vs.
subjective assessment, sleep dysfunction has long been considered a hallmark feature of
PTSD pathology (Ross et al., 1989). As previously noted, the relationship between
disturbed sleep and PTSD appears to be reciprocal. Previous research has suggested that
disturbed sleep in the wake of trauma is a risk factor for future PTSD development and
more severe PTSD symptomatology. Along these lines, Foa and colleagues (1995) found
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the presence of both sleep disturbance and nightmares following trauma predicted PTSD
in a sample of 158 female assault victims. The presence of trauma-related nightmares
following life-threatening injury was also associated with PTSD symptoms severity in a
sample of 60 patients hospitalized in a regional trauma unit (Mellman, David,
Bustamante, Torres, & Fins, 2001).
Although the implications of these findings are limited to some extent by crosssectional design, other prospective research has similarly demonstrated that disturbed
sleep is predictive of PTSD onset and PTSD symptom severity. Koren and colleagues
(2002) assessed 102 MVA survivors longitudinally for one year following their MVA.
Their findings revealed that a majority of the survivors experienced sleep difficulties
immediately following the accident; however, the severity of sleep difficulty was
predictive of later PTSD diagnosis (Koren et al., 2002). A comparable finding was
reported in a separate sample of MVA survivors such that both disturbed sleep and the
presence of nightmares one month following trauma predicted PTSD development six
months later (Harvey & Bryant, 1998). A more recent prospective study demonstrated
that sleep disturbance immediately prior to trauma exposure also increased risk for the
future development of PTSD (Bryant, Creamer, O’Donnell, Silove, & McFarlane, 2010).
In this study, a sample of traumatically injured hospital patients (N = 1033) were assessed
at the time of injury for current psychiatric disorders, including sleep dysfunction. Results
found that pre-trauma disturbed sleep predicted future onset of PTSD after controlling for
age, gender, mechanism of traumatic injury, severity of injury, and prior psychiatric
disorder.

4

Overall, the research suggests that disturbed sleep is common among individuals
with PTSD and may contribute to the maintenance of PTSD symptoms. Given the
apparent reciprocal nature of this relationship, an important goal for researchers is to
better understand the relation between disturbed sleep and PTSD. One factor that has
been largely excluded from this research base is the co-occurrence of sleep-disordered
breathing (SDB) in individuals with PTSD. Elevated rates of SDB have been observed
among individuals with PTSD (Krakow et al., 2000; Krakow et al., 2001); however,
many studies that have examined sleep-related difficulties in individuals with PTSD have
excluded individuals on the basis of a sleep-disordered breathing diagnosis. The
exclusion of SDB as a source of sleep disruption is important to recognize as individuals
with PTSD likely experience both psychogenic and organically manifested sleep
disturbance. Unfortunately, large proportions of individuals with a sleep-breathing
disorder are unaware of the underlying condition (Punjabi, 2008) and attribute ongoing
sleep difficulties to other factors. SDB may be an important factor contributing to the
high rates sleep disturbance reported, but not objectively observed in individuals with
PTSD, as well as a potent risk factor increasing a trauma survivors’ vulnerability to
develop clinically significant PTSD symptoms.
Sleep Disordered Breathing
Sleep-disordered breathing refers to a repetitive disruption of the respiratory
process during sleep. This disruption is generally attributed to an obstruction of the
airway and each interruption, referred to as an apnea, restricts airflow resulting in one or
more consecutively missed breaths. Although not all SDB is associated with subsequent
negative consequences, the International Classification of Diseases (ICD-10) designates
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that clinically significant SDB is defined as five or more episodes of apnea per hour of
sleep (Flemons, 2002). When this clinically significant sleep-disordered breathing is
accompanied by snoring as well as daytime sleepiness or fatigue the individual is at risk
for sleep apnea syndrome. The most prevalent form of sleep apnea is obstructive sleep
apnea (OSA). OSA is characterized by a complete or partial obstruction to the upper
respiratory tract during sleep that occurs despite adequate respiratory effort. Common
risk factors for OSA include increasing age, obesity, large neck circumference,
craniofacial abnormalities, and genetic predisposition (Levitzky, 2008; Punjabi, 2008).
For some individuals suffering from OSA, the sleep architecture is significantly altered,
including almost complete deprivation to rapid eye movement (REM) stage sleep as well
as stage 3 and stage 4 (deep) sleep due to repeated mid-sleep awakenings. Consequently,
individuals with OSA experience daytime sleepiness and fatigue; however, they may be
unaware of the cause.
Obstructive sleep apnea is associated with a range of negative outcomes. In
addition to fragmented sleep architecture and daytime fatigue, individuals suffering from
OSA are at risk for impaired memory, cognitive dysfunction, and significant medical
conditions including hypertension, obesity, and stroke (Phillipson, 1993; Wright, Johns,
Watt, Melville, & Sheldon, 1997). Given the health risks associated with OSA, early
identification and treatment is essential. The most effective form of treatment for OSA is
continuous positive airway pressure (CPAP). This technology delivers pressurized air to a
mask that covers the nose which is attached to the face by head straps. The continuous
positive pressure prevents the airway from collapsing during inhalation. The therapeutic
effect of treatment with CPAP is immediate and has been demonstrated with average
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nightly usage between 3.4-4.5 hours (Wright et al., 1997). In addition to the immediate
reversal of apneic episodes and increased density of REM stage sleep, treatment with
CPAP is associated with more distal benefits including a reduction in daytime
somnolence, improved mood, and increased alertness (Engelman et al., 1999; Jenkinson,
Davies, Mullins, & Stradling, 1999; Means et al., 2003; Schwartz, Kohler, & Karatinos,
2005).
Epidemiological research has estimated that more than 4% of adults suffer from
sleep apnea syndrome (Young et al., 1993). The majority of this published literature,
however, has examined the prevalence rates in age selected samples given the presence of
sleep apnea has been observed more frequently in older adult men (Ancoli-Israel, Kripke,
Mason, & Kaplan, 1985; Bixler, Vgontzas, Have, Tyson, & Kales, 1998). When
considering obstructive sleep apnea more specifically, few studies have investigated its
prevalence in the general population. One reason for this lack of research is that a formal
diagnosis of OSA can only be established through an overnight polysomnography
assessment. Punjabi (2008) conducted a literature review of available population-based
studies on the prevalence of OSA and estimated the prevalence of OSA is approximately
3 to 7% for adult men and 2 to 5% for adult women. One study that used overnight PSG
to examine a general population sample of men (n = 741) aged 20-100 found OSA
occurred in 3.3% of their sample with the highest prevalence (5%) occurring for ages 4564 (Bixler et al. 1998).
Apneic events associated with OSA can occur during any stage of sleep but more
commonly occur during REM stage sleep. REM stage sleep is characterized by an
increase in EEG activity which includes low amplitude-high frequency brain waves,
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sporadic rapid eye movement, and muscle paralysis (Carskadon & Dement, 2000).
During REM stage sleep the muscles of the upper airway become hypotonic which can
lead to a partial or complete obstruction that disrupts the flow of air (Strollo & Rogers,
1996; Youakim et al., 1998). The propensity of apneic episodes to occur during REM
sleep in OSA results in REM stage sleep fragmentation and an overall decrease in the
percentage of REM stage sleep (Strollo & Rogers, 1996).
Sleep Disordered Breathing and PTSD
Cross-sectional data suggest a strong association between sleep-disordered
breathing and PTSD (Krakow et al., 2000; Krakow et al., 2001; Orr et al., 2010; Youakim
et al., 1998). For example, an examination of 156 sexual assault survivors with PTSD
found approximately 55% reported symptoms consistent with a positive screen for SDB
(Krakow et al., 2000); however, in that study, the investigators did not confirm SDB
through polysomnographic assessment. A similar rate (54%) was reported for a sample of
patients with war-related PTSD who did undergo overnight polysomnography (Dagan,
Lavie, Bleich, 1991). In this study 13 of the 24 patients exhibited a pattern of respiratory
disturbance characteristic of SBD. A second study that utilized overnight
polysomnography to detect SDB (Krakow et al., 2004) found a slightly lower prevalence
(50%) rate in a sample of 78 fire evacuees seeking treatment for PTSD. A more recent
study analyzed the records of 80 soldiers (89.6% men; mean age = 37.7 years) who
recently returned from combat deployment and were diagnosed with PTSD (Orr et al.,
2010). Of the 80 soldiers, 58 underwent overnight polysomnography and 61% were
subsequently diagnosed with obstructive sleep apnea. Finally, in an uncontrolled study
examining crime victims (N = 44) with nightmares and PTSD, Krakow and colleagues
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(2001) found approximately 50% of the sample met diagnostic criteria for OSA. Taken
together, these data support the notion that SDB and PTSD frequently co-occur, and that
individuals with PTSD are at higher risk for SDB and OSA. Unfortunately, these studies
are limited by small samples and varying methodologies. Further research is needed to
provide a more accurate prevalence rate of these disorders among individuals with PTSD.
Potential pathways linking SDB to PTSD. The relationship between SDB or
OSA and PTSD has not been directly examined; however, similarities across several lines
of research have led to hypotheses about mechanisms potentially underlying this
relationship. The first of these hypotheses concerns REM stage sleep dysfunction as a
mechanism explaining co-morbid OSA and PTSD. This hypothesis posits that disturbed
sleep among individuals with PTSD involves altered REM sleep accrual or dysfunctional
REM sleep processes (Ross et al., 1989). Given the strong association between apneic
episodes and REM stage sleep dysfunction, the presence of OSA may be particularly
relevant to the development or exacerbation of PTSD symptoms. Dysfunctional REM
sleep mechanisms have been implicated as a possible pathway linking sleep dysfunction
to PTSD, although this theory has not been subjected to empirical scrutiny (Ross et al.,
1994). Some evidence suggests individuals with PTSD experience lower percentages of
REM stage sleep than do individuals without PTSD (Glaubman, Mikulincer, Porat, &
Wasserman, 1990; Habukawa et al., 2003). Other studies have observed greater REM
density and more rapid REM onset latency in individuals with PTSD (Mellman et al.,
1993; Ross et al., 1989), which may result from previous episodes of REM sleep
dysfunction. Regardless, dysfunctional REM stage sleep has been observed in individuals
with OSA and may be a risk factor for PTSD symptoms given that awakenings from
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REM stage sleep have been associated with a higher rate of reported nightmares and
associated physiological arousal (Mellman et al., 1995; Ross et al., 1989; Ross et al.,
1994).
Another potential pathway linking OSA to PTSD pertains to the possibility that
similar maladaptive health behaviors are prevalent among individuals with OSA and
individuals with PTSD. In particular, research has demonstrated strong associations
between obesity and both PTSD and OSA. As previously mentioned, obesity has been
associated with increased risk for OSA (Levitzky, 2008; Young et al., 1993), and it has
also been linked to PTSD. For example, a nationally representative survey of
approximately 13,000 individuals examined the association of obesity across mental
disorders and found that PTSD was most strongly associated with obesity (Scott, McGee,
Wells, Oakley-Browne, 2008). This association appears particularly pronounced among
veterans. A strong association between PTSD and obesity was observed in a large sample
of female veterans (n = 1259) such that the veterans who had screened positive for PTSD
concurrently demonstrated higher body mass index (BMI) than veterans not screening
positive (Dobie et al., 2004). Parallel findings were observed in a sample of male
veterans with PTSD such that the rate of obesity in veterans (46.5%) exceeded the
national average by 50% (Vieweg et al., 2006). Given the high rates of obesity found in
samples of individuals with PTSD, and its associated risk for OSA; individuals with
PTSD may be at greater risk to develop OSA due to poor health behaviors which lead to
obesity.
Despite the lack of a more comprehensive understanding between OSA and
psychiatric conditions like PTSD, the strong association observed between the two
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conditions has led to an increase in empirical inquiry. More recent research in this area
has examined whether or not successful treatment of OSA could result in amelioration of
PTSD symptoms more generally. If such a relationship was observed between successful
treatment of OSA and reduction in PTSD symptoms, those data might support the notion
that OSA contributes to the persistence of PTSD. No published investigation has
prospectively examined changes in PTSD symptoms following treatment for sleepdisordered breathing, but several studies have examined this relationship retrospectively.
For example, Krakow and colleagues (2000) examined existing hospital records of 23
patients treated with CPAP for sleep-disordered breathing that also presented with comorbid nightmares or PTSD. Post-treatment follow-up of these individuals revealed that
those patients that had maintained CPAP treatment reported a 93% improvement in sleep
and daytime functioning compared to a 33% improvement for patients who had not
complied with treatment. In addition, CPAP compliant patients reported an 85%
improvement in nightmares and 75% improvement in PTSD symptoms compared with a
10% and 45% worsening in symptoms respectively for the non-treatment compliant
individuals.
Similar results were reported in a single case evaluation of a 42-year male
Vietnam veteran with co-morbid PTSD and OSA (Youakim et al., 1998). In this instance,
the veteran was treated with CPAP for OSA and experienced immediate improvements in
sleep quality and quantity and an overall decrease daytime sleepiness. At 4-month
follow-up the veteran indicated considerable improvement in PTSD symptoms including
a decrease in nightmare frequency (from nightly to once a month) and intensity,
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diminished startle response, fewer re-experiencing symptoms. In addition the veteran
reported decreased frequency of re-experiencing symptoms.
Although not specific to PTSD, several studies were identified that examined
changes in depressive symptoms following CPAP treatment for obstructive sleep apnea
(Borak, Cieslicki, Koziej, Matuszewski, & Zielinkski; 1996; Engleman et al., 1999;
Engleman, Cheshire, Deary, & Douglas, 1993; Means et al., 2003; Schwartz et al., 2005).
For example, in a hospital sample (N = 50) newly diagnosed with OSA, the initiation of
CPAP treatment was associated with a reduction in self-reported depressive symptoms 46 weeks following treatment initiation (Schwartz et al., 2005). Similar findings were
reported for a sample (n = 21) of patients diagnosed with OSA (Engleman et al. 1996) in
which participants that “complied well” (n = 14) with CPAP treatment (i.e., >
4.5hrs./night) reported a significant reduction in depression score compared to individuals
(n = 7) utilizing their CPAP less. A third study identified examined 39 hospital
outpatients diagnosed with OSA following clinical evaluation with overnight
polysomnography. Results showed a statistically significant decrease in depressive
symptoms for the overall sample 3-month post treatment initiation. Of note, CPAP
compliance in this investigation was not found to be a significant predictor of change in
depressive symptoms; however, the authors noted the analyses approached statistical
significance. In the only study to implement a randomized placebo-controlled design,
Engelman and colleagues (1999) prospectively monitored depression symptoms in 34
patients presenting with mild OSA. Following random assignment to either CPAP or
placebo CPAP, they found patients utilizing CPAP reported significantly reduced
depression symptoms. Finally, one study was identified that failed to find a significant
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change in self-reported depressive symptoms following CPAP treatment for OSA (Borak
et al., 1996). This study assessed depressive symptoms in 20 men diagnosed with severe
OSA prior to CPAP treatment and again 3-months and 12-months following CPAP
initiation. Unfortunately, this study does not provide information on CPAP utilization
across the follow-up period, so it is unclear if the lack of change in depressive symptoms
was associated with CPAP compliance/noncompliance, severity of OSA, or a
combination of both factors. Given the lack of research examining the association
between PTSD and OSA, in addition to the symptom overlap for PTSD and depression
diagnoses, these studies provide more general support for the idea that successful
treatment OSA may be associated with improvements in concurrent psychiatric
functioning.
Although it is difficult to draw conclusions from this small literature base, this
research highlights the possibility of improvement in psychological symptoms following
successful treatment of co-morbid sleep disorders. To further investigate this potential
relationship, the current study prospectively monitored PTSD symptoms in veteran
sample initiating CPAP treatment for obstructive sleep apnea.
Hypotheses
The purpose of this study was to prospectively examine the associations between
CPAP treatment for obstructive sleep apnea and change in posttraumatic stress symptoms
in a sample of veterans. This study monitored change in posttraumatic stress symptoms,
subjectively rated indices of sleep quality and sleep difficulties, and trauma related
nightmares following OSA treatment implementation. The study design is quasiexperimental in nature, specifically a single group, pretest-posttest design that included
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two pre-treatment observations and two post-treatment observations. A nonequivalent
dependent variable was included, which allowed for the novel examination of CPAP
treatment on PTSD symptoms and other aspects of sleep functioning in the absence of a
true experimental design. In particular, the aims and corresponding hypotheses of the
study were as follows:
1. To examine whether participants who complied with CPAP treatment for OSA
realized a significant change in their posttraumatic stress symptoms compared to
pre-treatment severity.
Hypothesis 1: We predicted that participants who were compliant
(reporting an average of at least 4 hours/night over the post-treatment
monitoring period) with CPAP treatment would report a statistically
significant reduction in PTSD symptoms during post-treatment followup compared to pretreatment symptom severity.
2. To examine whether participants who complied with CPAP treatment for OSA
realized a significant improvement across indices of sleep quality and sleep
difficulties
Hypothesis 2a. We predicted that participants who were compliant
(reporting an average of at least 4 hours/night over the post-treatment
monitoring period) with CPAP treatment would report a statistically
significant increase in overall sleep quality during post-treatment
follow-up compared to pretreatment symptom severity.
Hypothesis 2b. We predicted that participants who were compliant
(reporting an average of at least 4 hours/night over the post-treatment
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monitoring period) with CPAP treatment would report a statistically
significant decrease in PTSD-related sleep dysfunction during posttreatment follow-up compared to pretreatment symptom severity.
3. To examine whether participants who complied with CPAP treatment for OSA
realized a significant improvement in nightmare-related distress compared to pretreatment report.
Hypothesis 3. We predicted that participants who were compliant
(reporting an average of at least 4 hours/night over the post-treatment
monitoring period) with CPAP treatment would report a statistically
significant decrease in nightmare-related distress during post-treatment
follow-up compared to pretreatment symptom severity.
4. To examine whether participants who complied with CPAP treatment for OSA
realized a significant improvement in daytime sleepiness compared to pretreatment report.
Hypothesis 4. We predicted that participants who were compliant
(reporting an average of at least 4 hours/night over the post-treatment
monitoring period) with CPAP treatment would report a statistically
significant decrease in daytime sleepiness during post-treatment followup compared to pretreatment symptom severity.
Method
Participants
Of the 489 veterans initially invited to participate, 70 were enrolled and
completed the baseline assessment. Of the 70 that completed the baseline assessment, 51
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participants were eligible for further participation (see Procedures for more detailed
information); however, only 47 completed at least one post-treatment follow-up
assessment. The final sample consisted of 47 veterans, who presented to the Neurology
Sleep Clinic at the Memphis Veteran Affairs Medical Center (VAMC) and at a minimum
completed the baseline assessment and one post-treatment assessment. The majority of
the sample was male (n = 42; 89.4%) and ages ranged from 31 to 69 years old (M =
53.53; SD = 10.27). A majority of the sample described themselves as either
White/Caucasian (n = 23; 48.9%) or Black/African American (n = 22; 46.8%) with one
individual (2.1%) selecting multiple racial descriptors and one (2.1%) declining to
specify. Just over half the sample (55.3%; n = 26) reported being involved in a
relationship with 24 participants currently married and two participants in a relationship
with a member of the opposite sex. Of the remaining participants, seven (14.9%) reported
they were currently single, 13 (27.7%) reported being divorced, and one participant
(2.1%) was widowed. CPRS medical record review found 31.9% (n = 15) of participants
had PTSD listed as an active diagnosis. Baseline sample characteristics are presented in
Table 1.
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Table 1
Baseline Sample Demographics
Total Sample

CPAP-compliant

CPAP Non-compliant

t-statistic

χ2

(df)
N

47

25

22

53.53 (10.27)

53.84 (11.19)

53.18 (9.38)

Male

42 (89.4)

21 (84.0)

21 (95.5)

.00

Female

5 (10.6)

4 (16.0)

1 (4.5)

1.80

White or Caucasian

23 (48.9)

14 (56.0)

9 (40.9)

1.07

Black or African American

22 (46.8)

10 (40.0)

12 (54.5)

.99

2 (4.3)

1 (4.0)

1 (4.5)

.01

7 (14.9)

3 (12.0)

4 (18.2)

.35

Age - M (SD)

t (45) = -.22

Gender – (%)

Race/Ethnicity - (%)

Other
Relationship Status - (%)
Single
*p ≤ .05. **p ≤ .01.

(table continues)
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Table 1 (continued)
Baseline Sample Demographics
Total sample

CPAP-compliant CPAP Non-compliant

t-statistic

χ2

(df)
Not married – in relationship (opposite sex)

2 (4.3)

1 (4.0)

1 (4.5)

.01

Married

24 (51.1)

13 (52.0)

11 (50.0)

.02

Divorced

13 (27.7)

8 (32.0)

5 (22.7)

.50

Widowed

1 (2.1)

0 (0.0)

1 (4.5)

1.16

BMI - M (SD)

33.58 (5.31)

33.91 (4.74)

33.20 (6.01)

t (44) = -.45

AHI - M (SD)

40.12 (28.36)

38.51 (29.17)

42.14 (27.95)

t (43) = .42

7.84 (4.19)

8.00 (4.40)

7.65 (4.02)

t (43) = -.28

15 (31.9)

9 (36.0)

6 (27.3)

Active Medical Diagnoses - M (SD)
CPRS Diagnosed PTSD – (%)
*p ≤ .05. **p ≤ .01.
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Measures
Eligible veterans who consented to participate completed a battery of
questionnaires that assessed various aspects of mental and physical health functioning
including traumatic event exposure, PTSD symptom severity, aspects of sleep and sleeprelated dysfunction, nightmares, and daytime functioning. Participants also reported on
their coping styles, physical health, and personality characteristics. A participant’s level
of CPAP compliance was assessed using a self-report daily sleep diary that included
specific assessment of nightly CPAP usage. Participants’ medical records were also
reviewed to extract body mass index (BMI; as calculated in the Neurology Sleep Clinic
polysomnographic report), active comorbid medical or psychiatric diagnoses, and 3month CPAP SmartCard data (as an objective index of CPAP compliance after
approximately 3-months of use). For a complete list of measures administered at each
time point refer to Table 2.
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Table 2
Timeline of Measurement Administration
Baseline

Pre-treatment – 1

Post-treatment – 1

Post-treatment – 2

Screening

Prior to CPAP*

2-weeks post

1-month post

CPAP

CPAP

Demographics

X

The Life Events Checklist

X

PTSD Checklist – Stressor Specific

X

X

X

X

Pittsburgh Sleep Quality Index

X

X

X

X

Epworth Sleepiness Scale

X

X

X

X

Nightmare Distress Questionnaire

X

X

X

X

X

X

X

X

X

X

X

X

Daily Sleep Diary (Compliance)
Short Form Health Survey 12

X

Brief COPE

X

Big Five Inventory

X

Note. * Pre-treatment 1 was completed as close to receipt of CPAP treatment, but prior to treatment initiation.
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Measures of Trauma Exposure and Post-traumatic Stress Disorder.
The Life Events Checklist (LEC; Gray, Litz, Hsu, & Lombardo, 2004). The
LEC is a 17-item self-report measure designed to screen for lifetime exposure to
potentially traumatic events. For each item, the participant is instructed to indicate
whether the event happened to them personally, if they witnessed the event, if they
learned about the event, if they are unsure the item applies, or the item does not apply to
them. For the purposes of this project, a brief follow-up assessment was conducted to
obtain more information about the most salient traumatic experience identified to verify
the trauma met Criterion A trauma exposure as specified in DSM-IV-TR (APA, 2000).
PTSD Checklist-Stressor - Specific Version (PCL; Weathers, Litz, Herman,
Huska, & Keane, 1993). The PCL is a 17-item measure that directly corresponds to the
DSM-IV-TR (APA, 2000) criteria for PTSD. The PCL utilizes a 5-point Likert scale
ranging from 1 (“not at all”) to 5 (“extremely”) and instructs participants to respond to
questions regarding the level of distress that was experienced related to each PTSD
symptom over the past month. The stem question “The event you experienced was:” is
specific to the PCL-S version and was pre-populated for all assessment time points
based on the worst traumatic event description provided during the preliminary
(baseline) trauma assessment. A full PTSD symptom severity score can be derived by
totaling the responses from all 17-items (range: 17-85) and specific PTSD symptom
subscale scores can be derived for the cluster B (“re-experiencing”), cluster C
(“avoidance/numbing”), and cluster D (“hypeararousal”) as defined by DSM-IV-TR
(APA, 2000). The PCL has demonstrated strong psychometric properties in other studies
of PTSD (Weathers et al., 1993; Yeager, Magruder, Knapp, Nicholas, & Frueh, 2007)
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and is well-validated in veteran samples (Grieger, Kolkow, Spira, & Morse, 2007; Keen,
Kutter, Niles, Krinsley, 2008; Pietrzak, Johnson, Goldstein, Malley, & Southwick,
2009). Previous research has found the PCL demonstrated sound test-retest correlation
coefficients of .88 after one week and .68 after two weeks (Ruggiero, Del Ben, Scotti, &
Rabalais, 2003). For the purposes of this study a screening cut-off score of ≥ 25 was
used to identify participants who are experiencing at least mild PTSD symptoms. This is
the suggested cut-off score when screening for PTSD in a primary care sample of
veterans (Prins, Kimerling, Yeager, & Magruder, 2010). For the purposes of this study,
the PCL-S instructions were modified for the follow-up assessments, instructing
participants to respond to questions in regard to their experience over the previous two
weeks.
Measures of Sleep, Sleep Disturbance, Nightmares, and Daytime Functioning
Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, &
Kupfer, 1989). The PSQI is a 19-item self report measure designed to assess sleep quality
and includes indices of sleep duration, sleep latency, and the frequency and severity of
sleep difficulties. The PSQI utilizes a 4-point Likert-type scale ranging from 0 (“not
during the past month”) to 3 (“three or more times a week”). The PSQI instructs
participants to respond to questions retrospectively about their experience in the past
month and to reply to the questions in a manner that is consistent with the majority of
days in the previous month. The PSQI can be used to derive seven component scores
(sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances,
use of sleep medications, and daytime dysfunction) which are summed together to yield a
Global Sleep Quality Index score (range: 0-21) with higher scores indicating more sleep
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difficulties and lower sleep quality. Qualitatively, a Global Sleep Quality Index of 5 or
greater indicates a “poor” sleeper (Buysse et al., 1998). The PSQI has demonstrated good
test–retest reliability, validity, and internal homogeneity (Buysse et al., 1989). Using a
cut-score of 5, the PSQI has demonstrated both high sensitivity (89.6%) and specificity
(86.5%; kappa = 0.75) in distinguishing good from poor sleepers (Buysse et al., 1989).
For this study, the PSQI instructions were modified for the follow-up assessments,
instructing participants to respond to with reference to the previous two weeks.
Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A; Germain, Hall,
Krakow, Shear, Buysse, 2005). The PSQI-A consists of seven self-report items that
assess the frequency of seven disruptive nocturnal behaviors (DNB) associated with
PTSD. These seven items assess the frequency of hot flashes, general nervousness,
memories or nightmares of trauma, anxiety or panic unrelated to trauma, nightmares
unrelated to trauma, night terrors during sleep, and episodes of acting out dreams. The
PSQI-A addendum is added to the PSQI’s original 19-item measure. The global PSQI-A
score of 4 produced a sensitivity of 94% and a specificity of 82% for discriminating
individuals with PTSD from those without PTSD. For the purposes of this study, the
PSQI-A instructions were modified for the follow-up assessments, instructing
participants to respond to questions in regard to their experience over the previous two
weeks.
Epworth Sleepiness Scale (ESS; Johns, 1991). The ESS is an eight item self
report questionnaire designed to provide a subjective estimation of daytime sleepiness.
The ESS utilizes a 4-point Likert-type scale ranging from 0 (“would never doze”) to 3
(“high chance of dozing”) and instructs participants to rate their usual level of sleepiness
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across eight common situations of daily living (e.g., “sitting and reading”, “watching
TV”, “as a passenger in a car for an hour without a break”). A total ESS score (range:
0-24) is calculated by summing the total of the eight items to derive an average sleep
propensity score. A score greater than 10 is typically considered outside normal limits
thus indicative of significant sleepiness (Johns, 1991). The ESS has demonstrated sound
test-retest reliability in both medically healthy normal sleepers and patients treated for
obstructive sleep apnea (Johns, 1992). The ESS has also been found to be sensitive to
sleep-disordered breathing severity demonstrating a linear relationship with sleep apnea
(Johns, 1993).
Nightmare Distress Questionnaire (NDQ; Belicki, 1992). The NDQ is a 13item self report measure designed to provide a measure of nightmare intensity. The scale
employs a Likert-type scale format to assess the frequency of nightmare related
emotional distress. The first 10 items are reversed scored and all 13 items provide a
summed total score ranging from 13-55, higher scores indicating higher levels of
nightmare related distress. Across four samples Belicki (1992) reported reliability
estimates ranging from .83 to .88. For the purposes of this investigation the time period
assessed was modified from “past year” to “past two weeks.”
Health Measure
Short Form Health Survey 12 (SF-12; Ware, Kosinski, & Keller, 1996). The
SF-12 is a 12-item self-report measure used to assess overall health functioning. The SF12 can be used to derive two subscales: the mental health component summary and the
physical health component summary. Two week test-retest correlations of .89 and .76
we found for the Physical component summary and mental health component summary
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respectively (Ware et al., 1996). The SF-12 has been used in a wide range of populations
and is considered a valid instrument.
Coping
Brief COPE (Carver, 1997). The Brief COPE is a 28-item self-report measure
used to examine an individual’s strategies of coping in response to stressful situations.
The measure is divided into 14 subscales which include (self-distraction, active coping,
denial, substance use, emotional support, instrumental support, behavioral
disengagement, venting, positive reframing, planning, humor, acceptance, religion, and
self-blame. The Brief COPE has been utilized in a range of populations including
veterans with mental health concerns (Moore, Varra, Michael, & Simpson, 2010).
Carver (1997) reported the internal reliabilities of the Brief COPE subscales to range
from .50 (venting) to .90 (substance use). The Brief COPE was administered to
participants during the baseline assessment.
Treatment Compliance
Daily Sleep Diary. The Daily Sleep Diary is a commonly used sleep measurement
technique. The measure included in this study was modified specifically for this project to
retrospectively assess both the characteristics of sleep and CPAP treatment compliance. For
each post-treatment assessment, the participant was instructed to complete a daily log of their
sleep habits including 1) time they got into bed the previous evening; 2) the time they got out
of bed in the morning; 3) length of time they used their CPAP machine; 4) a subjective rating
of overall sleep quality; and 5) any sleep medication use.
Side Effects Questionnaire (SEQ; Kribbs et al., 1993). The SEQ is a 22-item selfreport measure designed to assess the presence and severity of common side effects
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associated with CPAP use. Each side effect is rated on a scale from 0 (“not a problem”) to 3
(“a serious problem”). The SEQ was administered at the final follow-up assessment (posttreatment time point 2). The side effects scale was added to the active study protocol due to
elevated rates of CPAP non-compliance. Thererfore only a subset of participants (n = 24)
were adminstered this measure.
Personality
The Big Five Inventory (BFI; John, Naumann, & Soto, 2008). The BFI is a 44-item
self-report inventory designed to assess the Big Five personality dimensions of extraversion,
agreeableness, conscientiousness, neuroticism, and openness. The measure asks participants
to rate how much they agree with a series of short statements utilizing a 5-point Likert-type
scale ranging from 1 (“Disagree Strongly”) to 5 (“Agree Strongly”). For the purposes of this
study only the conscientiousness personality trait was measured. The purpose of the
conscientiousness scale is to serve as a non-equivalent dependent variable that is not
expected to change as a function of the CPAP treatment.
Procedure
Recruitment. Potential study participants were identified through the
computerized personalized record system (CPRS) as they were scheduled for an
overnight sleep study in the Neurology Sleep Clinic at the Memphis Veterans Affairs
Medical Center. Once identified, potential participants were screened through the
information available in their CPRS medical record and Neurology Sleep Clinic initial
consult. A participant was eligible for recruitment if they met the following criteria: 1) at
least 18 years of age; 2) no previous history of treatment with CPAP for sleep breathing
disorders; 3) no previously diagnosed Axis-I psychotic disorder; and 4) no indication of
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medical diagnosis (e.g., terminally ill) that could compromise their participation.
Participants meeting these initial eligibility requirements (N = 489) were sent a letter
explaining the purpose of the study and how the veteran may initiate participation in the
study or how to opt out of the project. Approximately 10 days after sending the contact
letter, if the participant had not initiated contact, the researcher followed up with potential
participants by telephone to ensure receipt of the recruitment letter and answer any
questions. Interested participants were scheduled for a baseline assessment prior to their
overnight sleep study. Following the recruitment letter, participants were also recruited
in-person at the Memphis VAMC. Potential participants were approached by research
staff in the waiting room of the Neurology Sleep Clinic the evening of their overnight
sleep study. Veterans were provided information about the research project and if
interested, completed the baseline assessment prior to the start of their overnight sleep
study.
During the baseline assessment, the researcher explained project procedures,
potential risks and benefits of participation, aspects of confidentiality, and provided the
rationale for the HIPAA release. All study participants provided informed consent and
HIPPA authorization if they chose to proceed with participation. In order to maintain
confidentiality eligible veterans who consented to participate were assigned an
alphanumeric participant identification number produced by a random number generator.
Assessment. Assessment for current study consisted of three phases: a baseline
screening assessment, a pretreatment follow-up phase, and a post-treatment follow-up
phase. A total of 70 participants were recruited for the baseline assessment and each
participant completed a battery of self-report questionnaires (for a complete list of
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measures administered at each time point see Table 2). Participants were not
compensated for completing the baseline assessment.
The second phase of the study consisted of a pre-treatment assessment which
occurred following the overnight sleep study, but prior to the receipt of the CPAP
machine. A participant was deemed eligible for the pretreatment follow-up phase if: 1)
they scored ≥ 25 on the baseline administration of the PCL-S and 2) were diagnosed with
OSA from their overnight PSG examination. Eligible and interested participants were
assessed prior to the receipt of their CPAP machine with the assessment measures
reflecting the veterans’ functioning and symptom experience over the previous two week
period. A total of 51 participants were eligible for the pretreatment phase; however, only
27 (52.9%) participants completed this assessment phase. Of the remaining 24
participants (47.1%), 18 were given their CPAP machine immediately following their
overnight sleep study (thus were unable to complete the pretreatment follow-up phase),
four participants were unable to be contacted for further participation, and two
participants did not complete the pretreatment assessment prior to CPAP treatment
initiation. Participants were compensated $10 for completing the pretreatment
assessment.
The third phase of the study consisted of two post-treatment follow-up
assessments. A veteran was deemed eligible for the post-treatment follow-up phase if
they met the following criteria: 1) completed a night the overnight sleep study; 2) were
diagnosed with OSA; and 3) received a CPAP machine. Participants meeting these
criteria were assessed two weeks following initiation of CPAP treatment (post-treatment
follow-up 1) and again four weeks following initiation of CPAP treatment (post-
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treatment follow-up 2) Forty-five participants (95.7%) completed the 2 week posttreatment follow-up and 44 participants (93.6%) completed the 4 week post-treatment
follow-up. Participants were compensated $5 for completion of each post-treatment
follow-up assessment. Figure 1 presents a flow chart of participant recruitment and
completion across the three phases of assessment. All study procedures were approved
through the university’s institutional review board (IRB) as well as the Memphis VAMC
(IRB) and Research and Development committee.
Data Analysis Plan
The following analyses evaluated the associations between CPAP compliance for
obstructive sleep apnea and change in PTSD symptoms, subjectively rated sleep
difficulties, daytime sleepiness, and nightmare distress after CPAP treatment initiation.
The final study sample (N = 47) consisted of veterans who, at a minimum, completed
the baseline assessment, had a PCL ≥ 25 at baseline, and completed at least one of the
post-treatment assessments.
Prior to conducting the analyses we examined the distributional properties of all
continuous variables. Using a criterion of 3.29 SD units from the mean (Tabachnick &
Fidell, 2005), there were no outliers on any variable in the dataset. We examined
whether the variables were skewed or kurtotic and found all variables demonstrated
acceptable distributional properties (all skewness and kurtosis values < 1.2) without
transformation.
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489 Veterans invited to participate

19 Veterans ineligible
 10 did not meet PCL inclusion criterion
 6 did not receive sleep apnea diagnosis
 3 did not pick-up their CPAP machine

70 Veterans completed Baseline (Time 1)

51 Veterans eligible for pretreatment follow-up

4 Veterans could not be contacted after baseline
27 Veterans completed the Pretreatment (Time 2)*
45 Veterans completed the Post-treatment 1 (Time 3)
44 Veterans completed the Post-treatment 2 (Time 4)
Figure 1. Flow chart of participant recruitment
Note. Of the 47 veterans eligible for pretreatment assessment, 18 received CPAP immediately following the overnight
polysomnography study, thus were unable to complete the pretreatment assessment.
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Baseline descriptive characteristics of the overall sample will be presented first,
including the demographic information (gender, age, ethnicity, relationship status) as
well as the means and standard deviations for the primary outcome variables (PTSD
symptom severity, overall sleep quality, PTSD-related sleep disruption, nightmare
distress, and daytime sleepiness). Baseline and pre-treatment descriptive characteristics
were compared between participants who were CPAP-compliant and those who were
non-compliant. We conducted T-tests and chi square analyses to assess any significant
differences between these groups prior to CPAP treatment initiation. Using independent
samples t-test, we compared the types of coping strategies used by individuals who were
CPAP complaints compared to strategies utilized by participants who were not CPAPcompliant. Finally, we compared participants who were CPAP-compliant and noncompliant on the rate of endorsement of different adverse side effects associated with
CPAP treatment.
The primary study analyses examined whether or not there was a statistically
significant difference between CPAP-compliant and non-compliant participants on selfreported PTSD symptom severity and indices of sleep disturbance at the follow-up time
points. Prior to testing the mixed models, relations between sample characteristics
(compliance status, BMI, and demographic variables) and the primary outcome
variables (PCL-S total score, PSQI Global Severity Index, PSQI-PTSD Addendum
score, NDS total score, and ESS total score) were explored using Pearson correlation
statistics. Next, a series of mixed-model repeated measures analyses were conducted to
compare CPAP-compliant and non-compliant participants on each of the primary
outcome variables (listed above) across the four time points. Mixed-effect models (also
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known hierarchical linear models or multilevel models) provide a flexible framework for
repeated measures analyses. Compared to traditional repeated measures analysis of
variance (ANOVA), mixed-effect models utilize all available data for each participant to
better accommodate for missing data (Gueorguieva & Krystal, 2004). For each model
tested, one of the primary outcome variables served as the dependent variable.
Demographic variables (i.e., gender, BMI, age, ethnicity, and relationship status) were
included as covariates in a model if they were found to be correlated at the p < .10 level
with group status (treatment compliant or non-compliant) or the respective primary
outcome variable of the model.
Planned post-hoc comparisons were conducted for any statistically significant
model effect or significant interaction. For all follow-up pairwise comparisons,
precautions were taken to adjust for the possibility of detecting a false positive (Type-I
error) significance level. We used the Bonferonni-Holm adjustment (Holm, 1979), to
adjust the acceptable α-level based on the number of independent analyses conducted on
our dataset (6). The Bonferroni-Holm procedure is adapted from the traditional
Bonferroni correction, which modifies the acceptable alpha (α) level based on the
number of comparisons being conducted. The traditional Bonferroni correction
calculates adjusted α as: α/k (where k = number of comparisons) to be applied to all
comparisons. This approach has been criticized as overly conservative and has the
tendency to reduce power significantly (Holm, 1979). Given the small sample size of the
current dataset, the modified Bonferroni-Holm adjustment was selected for its ability to
increase power while still correcting for the possibility of familywise Type-I error. The
Bonferroni-Holm adjustment calculates α based on the following procedure:
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1. Order the p-values from lowest to highest [p(1), p(2), … p(k)] for all
comparisons

2. Compare p(1) to α/k (where k = number of comparisons), if p(1) > α/k, then
reject null hypothesis 1.

3. Next, compare p(2) to α/(k-1), if p(2) > α/k-1, then reject null hypothesis 2.
4. Evaluate all comparisons to confirm or reject the null hypothesis.
The main study hypotheses had a maximum of six comparisons based on the four time
points evaluated. Using the standard p > .05 statistical significance level as the starting
α, Table 3 presents the adjusted p-values that will be applied to each comparison using
the Bonferroni-Holm adjustment.
As previously mentioned, this study included a non-equivalent dependent variable
as an additional measure of control in order to reduce threats to internal validity that are
associated with quasi-experimental designs (Coryn & Hobson, 2011). A non-equivalent
dependent variable serves as a control variable that is similar to the primary dependent
variables and is theoretically affected in the same way by threats inherent to a single
group pretest-posttest design, but different enough from the primary variables that it will
not be affected by treatment. Using the mixed-model repeated measures analyses
described above, we examined whether participants who were compliant with CPAP
treatment experienced change self-rated level of conscientiousness (the non-equivalent
dependent variable) compared to pretreatment self-rating.
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Table 3
Adjusted α-level Based on Bonferroni-Holm Adjustment for Pairwise Comparisons
Bonferroni-Holm
Ordered comparison (c)

equation

Adjusted α-level

α = .05/(k – c +1)
1

α = .05/(k – 1 +1)

.008

2

α = .05/(k – 2 +1)

.01

3

α = .05/(k – 3 +1)

.013

4

α = .05/(k – 4 +1)

.02

5

α = .05/(k – 5 +1)

.025

6

α = .05/(k – 6 +1)

.05

Note. k = total number of comparisons (6). c = Ordered comparison based on p-value
from least to greatest.
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Results
Sample Characteristics
Prior to completing the PCL-S, all participants (N = 47) identified at least one
potentially traumatic event using the Life Events Checklist. The most commonly reported
“worst” events were categorized as “combat or exposure to war-zone” (48.9%) and
“sudden, violent death” (10.6%). Other frequently endorsed “worst” events included “life
threatening illness or injury” (6.4%), “transportation accident” (6.4%), “physical assault”
(6.4%), and “exposure to toxic substances” (4.3%). At the baseline assessment the overall
sample had a mean PCL-S score of 56.83 (SD = 15.33). For individuals that completed
the pretreatment assessment (n = 28), the mean PCL-S score was 54.36 (SD = 14.09).
Baseline and pretreatment ratings were examined for measures of overall sleep
quality, PTSD-related sleep disturbance, nightmare distress, and daytime sleepiness. As a
whole, participants in the sample were considered poor sleepers (based on prior research,
which has suggested a cut score of 5 as the threshold for poor sleep), with a mean Global
Severity Index score of 14.30 (SD = 3.54) at baseline and 14.17 (SD = 3.12) at
pretreatment. Participants reported moderate levels of PTSD-related sleep dysfunction,
with means of 9.00 (SD = 5.25) and 9.64 (SD = 5.24) at baseline and pretreatment
respectively. The sample mean for nightmare-related distress was not in the elevated
range prior to CPAP treatment initiation, with mean severity scores of 31.39 (SD = 9.88)
at baseline and 29.54 (SD = 9.00) at pretreatment. The sample also an elevated level of
daytime sleepiness with mean severity scores of 10.52 (SD = 6.04) at baseline and 12.40
(SD = 5.93) at pretreatment Table 4 presents baseline and pretreatment descriptive
information for the primary outcome variables (PCL-S total scores, PSQI Global scores,
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PSQI-PTSD Addendum scores, NDS total scores, and ESS total scores) separately for
CPAP-compliant participants and non-compliant participants. There were no statistically
significant baseline or pretreatment differences between CPAP-compliant and noncompliant participants on any of the primary outcome variables.
In addition to the self-report questionnaires administered by study personnel,
participant’s medical records were reviewed to obtain two additional physical health
indicators, body mass index (BMI) and comorbid health conditions (total number of
clinician-diagnosed physical health conditions). Participant’s BMI was recorded as part
of their overnight sleep study at the Neurology Sleep Clinic. The Centers for Disease
Control and Prevention (2011) classifies BMIs of <18.5 as “underweight,” 18.5 to 24.9 as
“normal,” 25.0 – 29.9 as “overweight,” and > 30.0 as “obese.” Review of medical records
revealed the sample mean fell in the “obese” range at 33.59 (SD = 5.31). Twelve
participants (25.5%) were classified as “overweight” and 35 participants (74.5%) were
considered “obese.” There was not a statistically significant difference in BMI for CPAPcompliant and non-compliant participants. With respect to comorbid health conditions,
the mean number of active diagnoses (excluding mental health conditions) for the full
sample was 7.84 (SD = 4.19). There was not a statistically significant difference in the
number of active physical health conditions for CPAP-compliant and non-compliant
participants and this health index was not significantly correlated with any of the primary
outcome variables examined.
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Table 4
Baseline and Pre-treatment Descriptives across Time on PTSD Symptoms, Indices of Sleep, and Nightmare Distress compared
by CPAP Compliance Status
CPAP-compliant (n = 25)

CPAP Non-compliant (n = 22)

M (SD)

M (SD)

t-statistic

Baseline PCL-S

56.13 (15.64)

57.59 (15.31)

t (44) = .32

Pretreatment 1 PCL-S

54.13 (14.99)

54.62 (13.57)

t (26) = .09

Baseline GSI

13.76 (3. 81)

14.95 (3.15)

t (44) = 1.14

Pretreatment 1 GSI

14.25 (3.26)

14.08 (3.07)

t (27) = -.15

Baseline PSQI-PTSD

8.43 (5.10)

9.81 (5.50)

t (37) = .80

Pretreatment 1 PSQI-PTSD

9.43 (5.76)

10.00 (4.54)

t (20) = .24

PCL-S Total Score (PCL-S)

PSQI Global Severity Index (GSI)

PSQI-PTSD Addendum (PSQI-PTSD)

*p ≤ .05. **p ≤ .01.

(table continues)
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Table 4 (continued)
Baseline and Pre-treatment Descriptives across Time on PTSD Symptoms, Indices of Sleep, and Nightmare Distress compared
by CPAP Compliance Status
CPAP-compliant (n = 25)

CPAP Non-compliant (n = 22)

M (SD)

M (SD)

t-statistic

Baseline NDS

29.73 (9.17)

33.32 (10.56)

t (39) = 1.17

Pretreatment 1 NDS

28.15 (9.13)

30.92 (9.01)

t (24) =.78

Baseline EES

9.25 (6.16)

12.05 (5.67)

t (42) = 1.56

Pretreatment 1 EES

12.91 (6.20)

11.76 (5.78)

t (27) = -.51

Nightmare Distress Scale (NDS)

Epworth Sleepiness Scale (ESS)

*p ≤ .05. **p ≤ .01.

38

The apnea-hypopnea index (AHI) is an objective measure of OSA severity that
calculates the quantity of respiratory pauses (≥ 10 seconds in duration) during sleep per
hour. According to recommendations from the American Academy of Sleep Medicine
(Ruehland et al., 2009), AHI values between 5-15/hr are categorized a “mild OSA,”
values between 15-30/hr as “moderate OSA,” and values >30/hr as “severe OSA.”
Results from the Neurology Sleep Clinic’s sleep study report indicated 55.3% of the
current sample was rated as having severe OSA, 14.9% as moderate, and 25.5% as mild.
There was not a statistically significant difference in OSA severity between CPAPcompliant and non-compliant participants and AHI was not significantly correlated with
any of the primary outcome variables examined.
CPAP compliance. Subjectively reported CPAP utilization resulted in 27
participants being classified as CPAP-compliant, averaging 6.19 (SD = 1.50) hours per
night. The CPAP non-compliant group (n = 20) reported an average nightly usage of 1.11
(1.30) hours. A measure of objective CPAP compliance (retrieved from each veteran’s
CPAP “SmartCard,” an electronic device embedded in the CPAP equipment) was
retrieved through chart review following the 3-month follow-up visit with the Neurology
Sleep Clinic. Of the 47 total participants, SmartCard data was available for 23
participants. Although a direct comparison of CPAP utilization was not possible due to
the different follow-up periods for the current study and the Neurology Sleep Clinic (1month and 3-months respectively), the downloaded SmartCard data yielded a total days
of use index. We compared the self-reported total day CPAP usage to the SmartCard total
day usage and found SmartCard usage (total days used 3-months) was less than selfreported CPAP usage (1-month) for two participants. For these participants, the
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SmartCard indicated a total of 13 days of usage for one and 9 days of usage for the other.
We recalculated average nightly CPAP usage based on SmartCard indicated total days
used and average self-reported nightly use. For both participants, CPAP usage fell below
the cut-off ( ≥ 4) for treatment compliance, thus were reclassified as CPAP noncompliant. The final sample included 25 participants considered CPAP-compliant and 22
participants considered non-compliant.
Cross-sectional Comparisons by CPAP Compliance Status
Coping Strategies. Using independent samples t-tests, we compared the coping
strategies utilized by participants who were CPAP-compliant compared to participants
who were CPAP non-compliant. Of the 14 strategies measured by the Brief Cope
(Carver, 1997), differences emerged across two scales. Participants who were not CPAPcompliant reported using both “instrumental support” and “venting” significantly more
compared with participants who were CPAP-compliant (Table 5). No other statistically
significant group differences emerged for coping strategy utilization.
Side Effects of CPAP. The side effects associated with CPAP treatment were
measured at the four week follow-up time point. Using independent samples t-tests we
compared the side effects of CPAP endorsed by participants who were CPAP-compliant
compared with those who were non-compliant. Out of 21 side effects measured, results
found non-compliant participants reported significantly more problems associated with
CPAP mask irritation and CPAP-related sleep disturbance including more disturbed
sleep, more restlessness, and poorer sleep (Table 6). No statistically significant group
differences emerged for the 17 other side effects measured.
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Table 5
Comparison of Coping Strategies by CPAP Compliance Status
CPAP-compliant (n = 14)

CPAP Non-compliant (n = 13)

M (SD)

M (SD)

t-statistic

Self-distraction

5.29 (1.49)

5.15 (2.08)

t (25) = -.19

Active coping

4.79 (1.76)

5.77 (1.74)

t (25) = 1.46

Denial

5.00 (2.18)

4.31 (1.84)

t (25) = -.89

Substance use

3.54 (2.30)

3.54 (1.98)

t (25) = -00

Use of emotional support

3.57 (2.03)

5.08 (1.98)

t (25) = 1.95†

Use of instrumental support

3.21 (1.48)

5.69 (1.98)

t (25) = 3.76**

Behavioral disengagement

3.29 (1.48)

4.15 (2.11)

t (25) = 1.26

Venting

4.21 (1.48)

5.77 (2.01)

t (25) = 2.31*

Positive reframing

4.71 (1.68)

5.15 (1.68)

t (25) = .68

Planning

5.07 (1.86)

5.23 (1.48)

t (25) = .25

Coping Strategy

†

p < .10. *p ≤ .05. **p ≤ .01.

(table continues)
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Table 5 (continued)
Comparison of Coping Strategies by CPAP Compliance Status

†

CPAP-compliant (n = 14)

CPAP Non-compliant (n = 13)

M (SD)

M (SD)

t-statistic

Humor

3.57 (1.87)

3.77 (2.49)

t (25) = .24

Acceptance

5.29 (1.98)

6.38 (1.50)

t (25) = 1.62

Religion

5.64 (1.95)

6.15 (2.27)

t (25) = .63

Self-blame

4.57 (2.28)

5.38 (1.61)

t (25) = 1.06

p < .10. *p ≤ .05. **p ≤ .01.
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Table 6
Comparison of CPAP Side Effects by CPAP Compliance Status
CPAP-compliant (n = 15) CPAP Non-compliant (n = 9)
Side Effects

†

M (SD)

M (SD)

t-statistic

CPAP is too inconvenient to use

1.00 (1.13)

1.56 (.88)

t (22) = 1.26

The CPAP mark irritates my face

.87 (.99)

1.75 (.71)

t (21) = 2.23*

I can’t sleep because of the noise CPAP makes

.31 (.63)

.89 (1.05)

t (20) = 1.62

My eyes are irritated by CPAP

.67 (.90)

.78 (1.09)

t (22) = .27

The CPAP mask makes me claustrophobic

.53 (.92)

1.11 (.93)

t (22) = 1.49

My ears are irritated by the CPAP machinea

.13 (.35)

.56 (.88)

t (22) = 1.67

I have chest pains when I use CPAP

.13 (.35)

.11 (.33)

t (22) = -.15

I am embarrassed to use my CPAP

.33 (.62)

.44 (1.01)

t (22) = .34

My nose bleeds when I use CPAP

.27 (.46)

.22 (67)

t (22) = -.19

I have difficulty operating the CPAP machine

.13 (.35)

.11 (.33)

t (22) = -.15

The CPAP makes the bridge of my nose hurt

1.20 (1.21)

.78 (1.09)

t (22) = -.86

p < .10. *p ≤ .05. **p ≤ .01.

(table continues)
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Table 6 (continued)
Comparison of CPAP Side Effects by CPAP Compliance Status
CPAP-compliant (n = 15) CPAP Non-compliant (n = 9)
Side Effects

M (SD)

M (SD)

t-statistic

I have trouble putting on the CPAP mask

.20 (.56).

.22 (.44)

t (22) = .10

CPAP disturbs my sleep

.47 (.83)

1.89 (.93)

t (22) = 3.88**

CPAP gives me headaches

.20 (.56)

.11 (33)

t (22) = -.43

CPAP results in less intimacy with my bed

.47 (.74)

.25 (.46)

t (21) = -.75

CPAP makes my nose stuffy or drya

.47 (.64)

1.11 (1.27)

t (22) = 1.66

I toss and turn more with CPAP

.58 (.99)

1.67 (1.12)

t (22) = 2.34*

I sleep poorly with CPAP

.80 (1.15)

1.78 (.97)

t (22) = 2.14*

.29 (61)

.63 (1.19)

t (22) =.89

.71 (1.14)

1.57 (1.27)

t (22) = 1.57

partner

My bed partner sleeps worse when I use
CPAPa
I sleep worse when I use CPAP

Note. a Levene’s Test for Equality of Variances = p < .05, thus equal variances not assumed.
†

p < .10. *p ≤ .05. **p ≤ .01.
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Mixed-model Repeated Measures Analyses
Prior to testing the mixed models, relations between compliance status and
demographic variables and the primary outcome variables (PCL-S total score, PSQI
Global Severity Index total, PSQI-PTSD Addendum score, NDS total score, and ESS
total score) were explored using Pearson correlation statistics. Factors correlated at the p
< .10 level with compliance status or the primary outcome variables were included as
covariates in their respective models. Correlation analyses are presented in Table 7. For
the purposes of the current analyses, relationship status was recoded into a dichotomous
variable that reflected being in a relationship or not. This was necessary given that some
categories of relationship status had too few participants to allow for post-hoc
comparisons if found to be significant. The recoded relationship status variable resulted
in 26 participants being classified as involved in a relationship and 21 not currently
involved.
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Table 7
Correlation Matrix for Demographic Variables and Primary Outcome Variables
Variables

1

2

3

4

5

6

Sample Characteristics
1. Age

___

2. Gender

.05

___

3. Ethnicity

.02

.15

___

4. Relationship status

.11

-.38**

-.17

___

5. Body mass indexa

-.19

.19

-.03

.06

___

6. Treatment compliance status

.03

.19

-.14

.10

.07a

___

PCL-S total– Baselinea

-.11

-.06

.03

.11

-.30*b

-.05

PCL-S total – Pre-treatmentl

-.15

-.00

-.13

.32

-.09

.01

PCL-S total – Post-treatment 1b

.08

.01

.10

.05

-.29c

-.28

PCL-S total – Post-treatment 2c

.05

.03

.12

.04

-.19

-.21

PSQI global – Baselinea

-.05

.01

-.02

-.03

-.07b

-.17

PSQI global – Pre-treatmentl

-.19

-.16

-.07

-.10

.09

.03

PSQI global – Post-treatment 1c

-.10

.06

.12

-.01

-.04d

-42**

PSQI global – Post-treatment 2e

-.02

-.04

-.10

.16

-.08

-.20

PSQI-PTSD – Baselineh

-.06

-.16

.16

.17

-.27i

-.13

PSQI-PTSD – Pre-treatmentn

-.31

-.30

.11

.32

-.20

-.09

PSQI-PTSD – Post-treatment 1j

.01

-.05

.32†

-.12

-.05k

-.15

Outcome Variables

†

p < .10. *p ≤ .05. **p ≤ .01.

(table continues)
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Table 7 (continued)
Correlation Matrix for Demographic Variables and Primary Outcome Variables
Variables

1

2

3

4

5

6

PSQI-PTSD – Post-treatment 2j

-.03

-.19

.29†

.12

-.23

-.17

NDS total – Baselinea

-.01

-.12

.11

-.20

-.37*b

-.18

NDS total – Pre-treatmentl

-.26

-.20

-.08

-.43*

-.20

-.16

NDS total – Post-treatment 1b

-.17

.09

.16

-.09

-.34*c

-.14

NDS total – Post-treatment 2c

-.06

.02

.13

-.20

-.29†

-.15

ESS total – Baselinec

-.19

-.04

.07

.03

.06

-.23

ESS total – Pretreatmentl

-.23

.18

-.04

.23

.16

.04

ESS total – Post-treatment 1d

-.15

-.04

-.06

.07

.01e

-.16

ESS total – Post-treatment 2e

-.09

.13

.21

.05

.04

-.18

Conscientiousness – Baselined

.03

-.14

.11

.07

-.14e

.22

Conscientiousness – Pretreatmento

.36†

.09

.10

.09

-.32

.20

Conscientiousness - Post-treatment 1d

-.01

-.02

.13

.29†

-.06

.25

Conscientiousness Post-treatment 2d

-.02

.00

-.05

.18

-.14

.24

Note. PCL-S total = PTSD Checklist total score; PSQI global = Pittsburgh Sleep Quality
Index Global Severity Index; PSQI-PTSD = Pittsburgh Sleep Quality Index PTSD
Addendum total score; NDS total = Nightmare Distress Scale total score; ESS total =
Epworth Sleepiness Scale total score.
a

n = 46. bn = 45. cn = 44. dn = 43. en = 42. fn = 41. gn = 40. hn = 39. in = 38. jn = 37.

k

n = 36. ln = 27. mn = 26. nn = 20 o n = 28.

†

p < .10. *p ≤ .05. **p ≤ .01.
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Hypothesis 1. A 2 (group) x 4 (time) mixed-model repeated measures analysis
was conducted to compare participants who were CPAP-compliant to those who were
non-compliant on PTSD symptom severity. BMI was included as a covariate in this
model given the significant negative correlation with baseline PCL-S total score. The
results of this analysis did not show any statistically significant main effects (time, CPAP
compliance, or BMI); however, analyses did find a statistically significant compliance
status x time interaction (F(3, 102.15) = 5.66. p = .001). Follow-up Bonferonni-Holm
corrected pairwise comparisons (Table 8) revealed that CPAP-compliant participants
reported a statistically significant linear reduction in PTSD symptoms from pre to posttreatment, whereas non-compliant participants did not report a statistically significant
reduction from pre to post-treatment (Figure 2). For CPAP-compliant participants, the
estimated marginal means (EMM) for PCL score at the baseline (EMM = 56.14) and
pretreatment (EMM = 55.65) time points were significantly higher than the post-treatment
1 (EMM = 46.73) and post-treatment 2 (EMM = 47.03) time points. Non-compliant
participants reported a statistically significant reduction in PTSD symptoms from
baseline (EMM = 57.59) to pretreatment (EMM = 52.07), indicating a significant
reduction in PTSD symptoms prior to the treatment implementation. Further examination
of this decrease in PTSD symptoms from baseline to pretreatment revealed 5 out of the
13 non-compliant participants that completed pretreatment follow-up reported ≥ 9 point
decreases in symptoms from baseline to pretreatment. Of note, there was not a
statistically significant difference from baseline to pretreatment estimated marginal
means for the CPAP-compliant group. The CPAP-compliant and non-compliant groups
did not differ significantly from one another at pretreatment. Table 8 presents the means
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and standard deviations for each group across the four time points and Bonferonni-Holm
corrected pairwise comparisons are presented in Table 9.
A series of exploratory 2 (group) x 4 (time) mixed-model repeated measures
analyses were conducted to compare participants who were CPAP-compliant to those
who were non-compliant across the three DSM-IV-TR PTSD symptom domains
(reexperiencing, avoidance/numbing, and hyperarousal). These analyses failed to find
statistically significant main effects or significant interactions for reexperiencing (Figure
3) and avoidance/numbing (Figure 4) symptom domains. A trend level compliance status
x time interaction emerged for the hyperarousal symptom domain (F(3, 105.11) = 2.40. p
= .072). Despite this trend level finding, follow-up Bonferonni-Holm corrected pairwise
comparisons did not find a significant change in hyperarousal symptoms for either group
(CPAP-compliant or non-compliant) from pre-to-post treatment (Figure 5). Of note, when
we compared the estimated marginal means for CPAP-compliant and non-compliant
participants at each time point, we found a statistically significant difference at the
pretreatment time point such that non-compliant participants reported significantly more
hyperarousal symptoms compared to CPAP-compliant participants (Figure 5).
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Figure 2. Change over time in PTSD symptoms for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, posttreatment 1, n = 21, and post-treatment 2, n = 19.
*p ≤ .05. **p ≤ .01. ***p ≤ .001.
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Figure 3. Change over time in re-experiencing symptoms for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, posttreatment 1, n = 21, and post-treatment 2, n = 19.
*p ≤ .05. **p ≤ .01. ***p ≤ .001.
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Figure 4. Change over time in avoidance/numbing symptoms for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, posttreatment 1, n = 21, and post-treatment 2, n = 19.
*p ≤ .05. **p ≤ .01. ***p ≤ .001.
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Figure 5. Change over time in hyperarousal symptoms for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, posttreatment 1, n = 21, and post-treatment 2, n = 19.
*p ≤ .05. **p ≤ .01. ***p ≤ .001.
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Two additional exploratory 2 (group) x 4 (time) mixed-model repeated measures
analyses were tested that avoidance and numbing symptom domains separately. Analyses
revealed a significant compliance status X time interaction for avoidance symptoms (F(3,
107.47) = 2.96. p = .036). Follow-up Bonferonni-Holm corrected pairwise comparisons
revealed that participants who were not compliant with CPAP treatment reported a
statistically significant reduction in avoidance symptoms from the baseline (EMM = 7.93)
and pretreatment (EMM = 7.80) time points to post-treatment 1 (EMM = 6.06) time point
and between baseline and post-treatment 2 (EMM = 5.92) time points. CPAP-compliant
participants did not report a statistically significant change from pre-to-post treatment.
When we compared the estimated marginal means for CPAP-compliant and noncompliant participants at each time point, we found a statistically significant difference at
the baseline and pretreatment time points such that non-compliant participants reported
significantly more avoidance symptoms compared to CPAP-compliant participants. No
statistically significant main effects or interactions emerged for the model testing
numbing symptoms.
Hypothesis 2a. A 2 (group) x 4 (time) mixed-model repeated measures analysis
was conducted to compare CPAP-compliant and non-compliant participants on overall
sleep quality as measured by the PSQI Global Severity Index. Analyses revealed a
statistically significant compliance status x time interaction (F(3, 101.59) = 5.65. p =
.001). Follow-up Bonferonni-Holm corrected pairwise comparisons revealed that both
CPAP-compliant and non-compliant participants reported a statistically significant
improvement overall sleep quality from pre to post-treatment (Figure 6). For CPAPcompliant participants, the global severity index score at the baseline (EMM = 13.76)
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and pretreatment (EMM = 13.81) time points were significantly higher than the posttreatment 1 (EMM = 9.60) and post-treatment 2 (EMM = 10.56) time points. There was
not a statistically significant difference between baseline and pretreatment estimated
means for this group. For CPAP non-compliant veterans, the baseline time point (EMM
= 15.07) was significantly different from the post-treatment 2 (EMM = 12.13) time
point; however, there was not a statistically significant difference between the baseline
and post-treatment 1 (EMM = 13.15) time point or the pretreatment time point (EMM =
13.86) and either of the post-treatment time points (Table 9). Analyses also revealed a
statistically significant main effect for time (F(3, 101.59) = 13.12, p < .001) such that the
full sample showed improvement in overall sleep quality across time. Means and
standard deviations for each group are presented in Table 8.
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Figure 6. Change over time in overall sleep quality for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, posttreatment 1, n = 21, and post-treatment 2, n = 19.
*p ≤ .05. **p ≤ .01. ***p ≤ .001.
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Hypothesis 2b. A separate 2 (group) x 4 (time) mixed-model repeated measures
analysis was conducted on PTSD-related sleep dysfunction as measured by the PSQIPTSD Addendum. Ethnicity was included as a covariate in this model given the trend
level positive association with post-treatment 1 PSQI-PTSD total score (r = .32; p < .10)
and post-treatment 2 PSQI-PTSD total score (r = .29; p < .10). Analyses revealed
statistically significant main effects for time (F(3, 83.31) = 3.91, p = .012) such that the
full sample reported a mean reduction in PTSD-related sleep disruption from pre-to-post
treatment follow-up. Follow-up Bonferonni-Holm corrected pairwise comparisons (Table
9) showed a statistically significant reduction in reported PTSD-related sleep disruption
from the baseline (EMM = 9.00) and pretreatment (EMM = 8.58) time points to the posttreatment 1 (EMM = 6.93) time point. There was not a statistically significant difference
between any other time points. No statistically significant main effects emerged for
CPAP compliance status or ethnicity.
Hypothesis 3. A 2 (group) x 4 (time) mixed-model repeated measures analysis
was conducted to compare CPAP-compliant and non-compliant participants on nightmare
distress as measured by the Nightmare Distress Scale. Both BMI and relationship status
were included as a covariates in this model given significant associations with NDS total
score. Mixed model analyses revealed a statistically significant main effect for time (F(3,
105.08) = 3.91, p = .011) such that the overall sample reported a linear increase in
nightmare-related distress across time (see Figure 7). Follow-up Bonferonni-Holm
corrected pairwise comparisons revealed a statistically significant increase in reported
nightmare-related distress from the baseline (EMM = 28.03) time point to the posttreatment 1 (EMM = 30.38), and post-treatment 2 (EMM = 30.54) time points. However,
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post-hoc comparison also revealed a statistically significant increase in nightmare distress
from the baseline to pretreatment (EMM = 29.81) time point and no statistically
significant difference between the pretreatment time point and either post-treatment
follow-up time point (Table 9).
Hypothesis 4. A 2 (group) x 4 (time) mixed-model repeated measures analysis
was conducted to compare participants who were CPAP-compliant to those who were
non-compliant on daytime sleepiness as measured by the Epworth Sleepiness Scale
(Figure 8). Analyses failed to find any statistically significant main effects; however,
there was a statistically significant compliance status x time interaction (F(3, 100.87 =
3.60, p = .016). Follow-up Bonferonni-Holm corrected pairwise comparisons revealed a
statistically significant increase in reported daytime sleepiness from baseline (EMM =
8.85) to the pretreatment follow-up (EMM = 11.53) for the CPAP-compliant group. This
difference was not observed for CPAP non-compliant participants. There were no other
statistically significant differences on the pairwise comparison analyses for either group
(Table 9).
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Figure 7. Change in nightmare distress over time for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, posttreatment 1, n = 21, and post-treatment 2, n = 19.
*p ≤ .05; **p ≤ .01; ***p ≤ .001.
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Figure 8. Change over time in daytime sleepiness for CPAP-compliant and non-compliant participants.
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 23, and
post-treatment 2, n = 24. Sample sizes for the CPAP non-compliant group were: baseline, n = 20, pre-treatment, n = 13, posttreatment 1, n = 20, and post-treatment 2, n = 18.
*p ≤ .05; **p ≤ .01; ***p ≤ .001
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Non-equivalent Dependent Variable. A 2 (group) x 4 (time) mixed-model
repeated measures analysis was conducted to compare participants who were CPAPcompliant to those who were non-compliant on the non-equivalent dependent variable
conscientiousness as measured by the Big Five Inventory conscientiousness subscale.
Age and relationship status were included as covariates in the model given the trend level
positive associations with conscientiousness (Table 5). Analyses revealed a statistically
significant main effect for compliance status (F(1, 44.32) = 4.31, p = .044); however,
follow-up independent samples t-tests did not find a statistically significant difference
between CPAP-compliant and non-compliant participants on self-reported
conscientiousness at any of the four time points. No other statistically significant main
effects or interactions emerged from the model. These findings suggest there was not a
significant change in self-reported conscientiousness over time for either the CPAPcompliant or non-compliant participants.
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Table 8
Mean Scores across Time for the Primary Outcome Variables by Group Status
Outcome variable
Group status

T1

T2

T3

T4

Within-subjects effect size (d)

M (SD)

M (SD)

M (SD)

M (SD)

d1

d2

d3

d4

PCL-S total score
CPAP-compliant

56.13 (15.65) 54.62 (13.57) 46.83 (15.73)

47.16 (15.40)

.96

.96

.70

.68

CPAP non-compliant

57.59 (15.31) 54.62 (13.57) 55.33 (14.42)

53.53 (13.79)

.40

.21

-.08

.15

CPAP-compliant

13.76 (3.81)

14.25 (3.26)

9.63 (3.72)

10.56 (4.52)

1.17

.75

1.52

.92

CPAP non-compliant

14.95 (3.15)

14.08 (3.07)

13.20 (4.27)

12.29 (3.82)

.70

1.06

.51

.75

CPAP-compliant

8.43 (5.11)

9.43 (5.76)

6.59 (5.35)

6.73 (5.24)

.40

.38

.81

.82

CPAP non-compliant

9.81 (5.50)

10.00 (5.54)

8.20 (5.58)

8.57 (5.58)

.59

.42

1.45

.67

PSQI Global Severity Index

PSQI-PTSD Addendum

(table continues)
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Table 8 (continued)
Mean Scores across Time for the Primary Outcome Variables by Group Status
Outcome variable

T1

T2

T3

T4

M (SD)

M (SD)

M (SD)

M (SD)

d1

d2

d3

d4

CPAP-compliant

29.73 (9.17)

28.15 (9.13)

28.32 (8.00)

27.00 (9.58)

.26

.35

-.03

.18

CPAP non-compliant

33.32 (10.56)

30.92 (9.01)

31.11 (11.68)

29.78 (9.23)

.33

.60

-.03

.23

CPAP-compliant

9.25 (6.16)

12.91 (6.20)

9.59 (6.22)

9.33 (5.71)

-.07

-.02

1.05

2.13

CPAP non-compliant

12.05 (5.67)

11.77 (5.77)

11.50 (5.68)

11.28 (4.74)

.24

.16

.10

.15

Group status

Within-subjects effect size (d)

Nightmare Distress Scale

Epworth Sleepiness Scale

Note. The within-subjects Effect size was calculated using Morris and DeShon’s (2002) equation 8, which corrects for the
dependence between repeated measure means. Baseline (T1) sample sizes: CPAP-compliant (n = 25) and CPAP noncompliant (n = 22). Pretreatment 1 (T2) sample sizes: CPAP-compliant (n = 15) and CPAP non-compliant (n = 13). Posttreatment 1 (T3) sample sizes: CPAP-compliant (n = 24) and CPAP non-compliant (n = 21). Post-treatment 2 (T4) sample
sizes: CPAP-compliant (n = 25) and CPAP non-compliant (n = 19). d1 = T1 & T3 within-subjects effect size; d2 = T1 & T4
within-subjects effect size; d3 = T2 & T3 within-subjects effect size; d4 = T2 & T4 within-subjects effect size.
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Table 9
Follow-up Comparison of the Estimated Marginal Means from the Mixed-model Repeated Measures Analyses Separated by
Group Status
Outcome variable
Group status

T1

T2

T3

T4

EMM (SE)

EMM (SE)

EMM (SE)

EMM (SE)

Significant comparisons

56.14 (2.97)

55.65 (3.15)

46.73 (2.97)

47.03 (2.96)

T1 > T3***, T1 > T4***

PCL-S total score
CPAP-compliant

T2 > T3***, T2 > T4***
CPAP Non-compliant

57.59 (3.22)

52.07 (3.41)

55.03 (3.23)

53.46 (3.58)

T1 > T2**

Overall Sample

56.86 (2.19)

53.86 (2.30)

50.88 (2.36)

50.25 (2.20)

(Not interpreted)

13.76 (.77)

13.81 (.85)

9.60 (.77)

10.56 (.77)

T1 > T3***, T1 > T4***

PSQI Global Severity Index
CPAP-compliant

T2 > T3***, T2 > T4***
CPAP Non-compliant

15.07 (.83)

13.86 (.90)

*p < .05. **p < .01. ***p < .001.

13.15 (.84)

12.13 (.88)

T1 > T4**
(table continues)
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Table 9 (continued)
Follow-up Comparison of the Estimated Marginal Means from the Mixed-model Repeated Measures Analyses Separated by
Group Status
Outcome variable

T1

T2

T3

T4

Group status

EMM (SE)

EMM (SE)

EMM (SE)

EMM (SE)

Significant comparisons

Overall Sample

14.41 (.56)

13.84 (.62)

11.37 (.57)

11.35 (.58)

(Not interpreted)

CPAP-compliant

8.73 (1.13)

9.11 (1.22)

6.54 (1.13)

7.04 (1.13)

(Not interpreted)

CPAP Non-compliant

9.28 (1.33)

8.06 (1.44)

7.32 (1.33)

8.44 (1.35)

(Not interpreted)

Overall Sample

9.00 (.86)

8.58 (.93)

6.93 (.86)

7.74 (.87)

CPAP-compliant

29.73 (1.33)

31.41 (1.42)

32.54 (1.34)

32.01 (1.33)

(Not interpreted)

CPAP Non-compliant

26.33 (1.49)

28.12 (1.59)

28.23 (1.48)

29.07 (1.49)

(Not interpreted)

Overall Sample

28.03 (.98)

29.81 (1.03)

30.38 (.98)

30.54 (.98)

PSQI-PTSD Addendum

T1 > T3**, T2 > T3**

Nightmare Distress Scale

T1 > T3**, T1 > T4**
T1 > T2**

*p < .05. **p < .01. ***p < .001.

(table continues)
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Table 9 (continued)
Follow-up Comparison of the Estimated Marginal Means from the Mixed-model Repeated Measures Analyses Separated by
Group Status
Outcome variable

T1

T2

T3

T4

Group status

EMM (SE)

EMM (SE)

EMM (SE)

EMM (SE)

Significant comparisons

CPAP-compliant

8.85 (1.16)

11.53 (1.24)

9.83 (1.17)

9.29 (1.17)

T2 > T1**

CPAP Non-compliant

12.26 (1.26)

11.20 (1.31)

11.49 (1.24)

10.45 (1.27)

Overall Sample

10.55 (.86)

11.36 (.90)

10.66 (.85)

9.87 (.87)

(Not interpreted)

CPAP-compliant

34.36 (1.47)

35.34 (1.56)

36.04 (1.48)

35.99 (1.47)

(Not interpreted)

CPAP Non-compliant

30.63 (1.58)

31.49 (1.67)

32.14 (1.58)

31.65 (1.60)

(Not interpreted)

Overall Sample

32.49 (1.08)

33.41 (1.14)

34.09 (1.08)

33.81 (1.09)

(Not interpreted)

Epworth Sleepiness Scale total

Conscientiousness Scale

Note: Significant pairwise comparisons by group status were only interpreted if indicated by a significant compliance status x
time interaction for the respective model. Significant pairwise comparisons for the overall sample were only interpreted if
indicated by a significant main effect for time for the respective model. T1 = Baseline assessment; T2 = Pretreatment
assessment; T3 = Post-treatment 1 assessment; T4 = Post-treatment 2 assessment.
*p < .05. **p < .01. ***p < .001.
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Discussion
The purpose of this investigation was to expand on previous research that has
examined the relationship between PTSD and sleep-disordered breathing. Specifically,
this study prospectively examined posttraumatic stress symptoms following CPAP
treatment for obstructive sleep apnea in a veteran population. We hypothesized that
veterans compliant with their CPAP treatment would realize improvement in PTSD
symptoms compared to pretreatment levels. Consistent with this hypothesis, and in line
with previous retrospective work (Krakow et al. 2000; Youakim et al. 1998), our findings
indicated that successful treatment of OSA with CPAP was associated with a subsequent
reduction in PTSD symptoms. For veterans who were not compliant with CPAP
treatment, no significant change in PTSD symptoms was observed.
Given this pattern of results, we also conducted follow-up analyses to investigate
the possibility that the influence of successful CPAP treatment on PTSD symptoms may
be more pronounced on one or more of the specific PTSD symptom domains
(reexperiencing, avoidance/numbing, and hyperarousal). Interestingly, our mixed model
repeated measures results did not show statistically significant effects for any one specific
PTSD symptom domain. Although the interpretability of these follow-up analyses was
limited by low statistical power, these results suggest that improvement in OSA is
associated with a generalized pattern of reduction in PTSD-related distress, not specific
to any cluster of symptoms. This finding is somewhat less intuitive given that PTSDrelated sleep disturbance is specifically measured by the reexperiencing and hyperarousal
symptom domains. One possible explanation for our findings is that OSA-related sleep
disturbance may be functionally different than PTSD-related sleep disturbance. For
instance, it is well-established in the literature that OSA is related to poor sleep quality,
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sleep maintenance, and daytime fatigue (Phillipson, 1993; Wright et al., 1997) whereas
the most commonly reported PTSD-related sleep dysfunction is difficulty with sleep
initiation, sleep maintenance, and nightmares. Thus, the improvement in sleep processes
associated with the successful treatment of obstructive sleep apnea may not overlap
entirely with PTSD specific sleep disturbance. Another possibility is that the
improvement in sleep quality associated with successful treatment of OSA may be
associated with subsequent improvements in psychological functioning more generally
and may not be entirely specific to PTSD. Although this latter hypothesis cannot be ruled
out, it is less likely given the significantly elevated rates of OSA observed in samples of
PTSD compared with general population samples (Krakow et al., 2000; Krakow et al.,
2001; Orr et al., 2010; Youakim et al., 1998).
Nonetheless, the present findings provide additional support to previous
retrospective work suggesting that the successful treatment of OSA with CPAP may also
reduce posttraumatic stress symptoms. These results are encouraging and may have
important clinical implications. For example, treatment providers working with Veterans
with PTSD may wish to incorporate appropriate OSA screening measures in addition to
assessing for more behaviorally-based (PTSD-related) sleep disturbance. For veterans
with untreated concurrent obstructive sleep apnea, PTSD symptoms may be exacerbated
and sleep disturbance may not fully resolve with PTSD treatment alone. In addition, sleep
processes have been proposed as an important factor in emotional memory processing
and emotion regulation (van der Helm & Walker, 2009). Research suggests that the
ability to encode new information as well as consolidate new information into long-term
memories is heavily sleep-dependent processes (Walker, 2009; Walker & Stickgold,
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2004). Given that several current PTSD treatments hypothesize that symptom resolution
occurs as a result of successful traumatic memory (re)processing (see Prolonged
Exposure - Foa, Hembree, & Rothbaum, 2007; Cognitive Processing Therapy - Resick,
Monson, & Chard, 2008), untreated concurrent conditions such as OSA that impact sleep
processes may result in the reduced efficacy of these trauma processing oriented PTSD
treatments. Treatment providers working with individuals with PTSD may enhance
treatment outcomes by ensuring adequate identification and treatment compliance for
physical sleep disorders like OSA.
Unfortunately the research highlighted across these areas is ongoing and the
mechanisms underlying the relationship between PTSD and OSA are unknown. At
present, theories regarding the possible impact that OSA has on PTSD treatment are
speculative. Substantially more research is needed to better define the possible
mechanisms linking PTSD and OSA. It is possible that pre-existing or sub-threshold
OSA may place individuals at greater risk to develop PTSD following a traumatic event
or conversely, that individuals experiencing PTSD-related sleep disturbance may confer
increased risk to develop OSA.
Other Aspects of Psychological Functioning
In addition to PTSD symptoms, the current study prospectively evaluated several
other aspects of psychological functioning among veterans receiving CPAP treatment for
OSA. The first factor examined was self-reported sleep quality. We hypothesized that
veterans who complied with the CPAP treatment would realize an improvement in
perceived sleep quality relative to their respective pre-treatment ratings. Mixed-model
analyses revealed a statistically significant effect of time, such that the overall sample
reported an improvement in sleep quality from pre-to-post treatment. This finding was
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somewhat surprising considering participants who were not CPAP-compliant would not
be expected to see a reduction in sleep disturbance related to OSA. Although the
improvement in sleep quality for CPAP non-compliant participants was somewhat less
pronounced compared to the reduction for CPAP-compliant participants, it was
statistically significant. A similar finding emerged for the second factor, PTSD-related
sleep dysfunction, whereby the overall sample reported an improvement in PTSD-related
sleep dysfunction from pre-to-post treatment. No significant differences were found for
individuals that were CPAP-compliant compared to those who were non-compliant.
One possible explanation for these findings is that participants may have altered
their sleep habits in ways other than implementing the CPAP treatment. For example, all
participants met with a member of the Neurology Clinic staff following their overnight
sleep study. In addition to reviewing the results of the study and diagnostic
considerations, these veterans were given information on improving sleep hygiene.
Participants were also encouraged to make lifestyle changes, including losing weight and
reducing alcohol consumption, as ways to decrease OSA severity. It is possible that
participants, who chose not to utilize their CPAP treatment at the optimal therapeutic
level, implemented other changes to their sleep routine or lifestyle which may have led to
an improvement in perceived sleep quality. Although the current study did not evaluate
behavioral modifications to the sleep routine, it is possible that CPAP utilization,
improvements in sleep hygiene, or a combination of both resulted in the overall sample
reporting increased sleep quality and decreased PTSD-related sleep dysfunction. Another
possibility is that these findings are explained, simply by the phenomenon of regression
to the mean.
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Nonetheless, it is encouraging that in a sample of veterans diagnosed with OSA in
addition to reported PTSD-related distress, that improvements in sleep can be realized. It
is important to note that the current study was underpowered to detect differences
between the groups. Future studies examining sleep indices among individuals with OSA
and PTSD may wish to simultaneously monitor multiple aspects of sleep behavior in
addition to CPAP compliance. In addition, a longer-term follow-up period would be
helpful to determine whether or not the observed change in perceived sleep quality found
in this study represent sustainable improvement across time.
In addition to measures of sleep quality, this study examined a third factor,
nightmare-related distress. We hypothesized that participants who were CPAP-compliant
would report decreases in nightmare-related distress compared to pre-treatment report.
Contrary to our hypothesis, results did not show a significant post-treatment improvement
in nightmare-distress compared to pretreatment report. Of note, a significant increase in
nightmare distress was reported from the baseline time point to pretreatment time point
for the full sample; however, no significant differences were found between the
pretreatment time point and either post-treatment time point. This finding was
unexpected, given that previous cross-sectional research suggested that successful
treatment of OSA with CPAP was associated with subsequent reductions in nightmare
frequency and intensity (Krakow et al., 2000 & Youakim et al., 1998). One hypothesis
proposed to explain these previous results is that the dysfunction in REM stage sleep
attributed to OSA may be associated with an increase in nightmare experience for
individuals with PTSD, as dreaming/nightmares is more frequently reported following
REM stage sleep awakening compared with awakening from non-REM sleep (Hobson
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1988). The current results do not support previous cross-sectional findings as no
significant change in nightmare distress was observed for CPAP-compliant individuals
who would be expected to demonstrate decreased awakenings during REM stage sleep
following successful OSA treatment.
Our findings are more consistent with a literature review conducted by Whittman
and colleagues (2007) that concluded the occurrence of posttraumatic nightmares
throughout the sleep cycle could not be explained by exclusively by altered REM sleep,
thus the improvement in REM stage sleep density associated with CPAP treatment would
not be expected to decrease nightmare distress related to the occurrence in nightmares
across other sleep stages. It is important to note, however, that the Nightmare Distress
Scale used in the current study measures nightmare-related distress and not the frequency
in which nightmares occurred. Thus it is unclear if CPAP-compliant individuals in the
sample may have experienced fewer nightmares producing an equivalent level of distress
or if no change in the experience (frequency or intensity) of nightmares occurred overall.
Furthermore, comparisons regarding change in nightmare distress from pre-to-post CPAP
treatment may have limited by a low rate of nightmare endorsement at the baseline (M =
31.39; SD = 9.88) and pretreatment (M = 29.54; SD = 9.00) time points. The rate of
nightmare endorsement in this study may reflect the fact that the sample was not recruited
based on a diagnosis of PTSD, but rather comprised of individuals that endorsed a range
of posttraumatic stress symptoms.
A final factor examined by this study was daytime somnolence. Subjectively
reported daytime somnolence is a well-recognized symptom of untreated OSA. Research
has long demonstrated that successful resolution of OSA with CPAP results in an almost
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immediate reduction of daytime somnolence (Engelman et al., 1999; Jenkinson et al.,
1999; Kribbs et al., 1993). Our analyses were inconsistent with this line of research as
results did find a change in daytime somnolence among CPAP-compliant participants.
Although unanticipated, there are several possible explanations for the current results.
First, as previously acknowledged, the current study was statistically underpowered and it
is possible that if a daytime somnolence effect was present, it was too small for the
current sample size to detect. Another possibility is that veterans in the CPAP-compliant
group, although averaged ≤ 4 hours of use, may not have used their CPAP at the optimal
therapeutic level every night. To this point, a study conducted by Kribbs and colleagues
(1993) found that sleeping without CPAP for a single night resulted in almost complete
reversal of daytime alertness gains derived from sleeping with CPAP. Follow-up
inspection of the current sample revealed only 32% (n = 8) of the CPAP-compliant group
reported utilizing the CPAP machine at the optimal therapeutic level for all 28 days of the
follow-up period. A final possibility is that in a proportion of individuals with OSA and
concurrent psychopathology, OSA may not be the principal cause of daytime somnolence
(Antic et al. 2010). For example, in a general population sample, depression was found to
be the most significant risk factor for daytime somnolence followed by BMI, age, sleep
duration, diabetes, smoking, and lastly OSA (Bixler et al., 2005). Posttraumatic distress
has not been directly examined in this regard; however, given the findings in the Bixler
(2005) study, it is possible that daytime somnolence may be influenced by psychological
conditions like PTSD and successful treatment of OSA may not alleviate more
psychopathological-related daytime somnolence.
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Cross-sectional Comparisons by CPAP Compliance Status
The current study examined several factors thought to be associated with CPAPcompliance and non-compliance. First we examined coping strategies and found that
participants who were not CPAP-compliant endorsed using both the avoidant strategy of
“venting” as well as “instrumental support” coping at significantly higher rates than
CPAP-compliant participants. In regard to venting, research has consistently linked
avoidance style coping, including venting, to worse functional health outcomes including
more severe PTSD symptoms (Aldwin & Revenson, 1987; Ashton et al., 2005; Penley,
Tomaka & Wiebe, 2002; Tiet et al., 2006). Given this relationship, it is not surprising that
we observed a correlation between higher levels of venting, CPAP-noncompliance, and
sustained posttraumatic stress symptoms. Conversely, CPAP non-compliant participants
also reported using a significantly higher level of instrumental support compared to
CPAP-compliant participants. Instrumental support is considered to be a problem-focused
(or approach-focused) coping strategy, which has been found to be associated with more
positive health-related outcomes (Penley et al., 2002). Instrumental support largely
consists of providing or seeking out tangible goods and services to assist with problem
solving. Research examining spousal support in relation to CPAP compliance has found
that an individual’s perception of spousal support only predicted compliance in
individuals with severe OSA (Baron et al., 2011). Furthermore, this study found that
perceived spousal pressure to use CPAP was associated with lower CPAP adherence
rates. Although perceived support or pressure for CPAP use was not measured in the
current study, the higher rates of instrumental support used among CPAP non-compliant
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individuals warrant further investigation given the low rates of CPAP compliance
observed in individuals with OSA.
We also compared the endorsement of side effects associated with CPAP
treatment among participants who were CPAP-compliant and non-compliant. Participants
who were not CPAP-compliant reported significantly more problems across several areas
including more problems with mask irritation and more CPAP-related sleep disturbance.
These findings are consistent with previous research suggesting that greater endorsement
of perceived CPAP side effects is positively associated with treatment noncompliance
(Engleman, Martin, & Douglas, 1994).
Methodological Considerations
This study had several notable limitations that should be considered when
interpreting the current findings. As previously noted the sample size was small and
likely limited the strength of our analytic approach to further examine change in PTSD
symptoms and other aspects of psychological functioning. Previous research has
demonstrated the difficulties of conducting longitudinal research with clinical
populations (Coen & Patrick, 1996; Patel, Doku, & Tennakoon, 2003), which include
difficulty recruiting and retaining participants. Although the high retention (95.7% at
post-treatment 1 time point & 93.6% at post-treatment 2 time point) was a strength of the
current study, we also sought to limit the impact of a small sample size and attrition by
utilizing a mixed-modeling repeated measures statistical approach. Mixed-effect models
provide a flexible framework for repeated measures analyses by utilizing all available
data for each participant (Gueorguieva & Krystal, 2004). In addition, we took precautions
to decrease the likelihood of detecting Type-I error by subjecting all post-hoc model
comparisons to a Bonferonni-Holm adjustment (Holm, 1979).
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Another limitation of the current study is the lack of random assignment to study
groups. This research study was designed to be quasi-experimental in nature in order to
examine change in PTSD symptoms following CPAP treatment initiation for OSA as
prescribed by the VA Neurology Sleep Clinic. Study groups (CPAP-compliant or CPAP
non-compliant) were created following the conclusion of all data collection. Although
random assignment to study groups is preferable, temporal and logistical restraints, in
addition to the potential adverse health consequences of randomly assigning individuals
to use or not use their CPAP treatment limited this study’s internal validity. To attend to
this issue and potentially reduce threats to internal validity, the current study
implemented a non-equivalent dependent variable as an additional measure of control on
the impact of CPAP treatment on PTSD symptoms. Results found that participants did
not report a change in conscientiousness level (non-equivalent dependent variable) from
pre-to-post treatment. The lack of observed change in reported conscientiousness
provided additional strength to the finding that successful treatment of OSA is associated
with reductions in PTSD symptoms.
Some additional limitations worth noting concern the generalizability and stability
of current findings. Of the 489 participants invited to participate in this project, 71
(14.5%) completed the baseline assessment. It is possible that this self-selected sample is
not characteristic of the veteran population more generally. The sample was
predominantly male (89.2%), thus it is unclear if these results would hold consistent
among female veterans. Additionally, this study measured posttraumatic stress symptoms
and not posttraumatic stress disorder. Although we used a well-known and validated
measure of PTSD symptoms (PCL-S) we did not have the ability to conduct structured
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clinical interviews to make formal PTSD diagnoses. Future studies should consider using
a diagnostic measure of PTSD like the Clinician Administered PTSD Scale (Blake,
Weathers, Nagy, & Kaloupek, 1995) as it would allow for diagnostic comparisons as well
as a more nuanced examination of change in PTSD symptoms. In regard to CPAP
compliance, participants in this study self-reported usage. In two cases, follow-up with
objective measurement at three months indicated exaggerated CPAP use. Given the selfreported follow-up period (1-month) represented approximately one-third of the objective
SmartCard review (3-month), it is possible other participants may have exaggerated their
use and went undetected. To avoid this limitation and increase sensitivity to the level of
CPAP treatment adherence, future studies incorporate objective measurement of CPAP
utilization across follow-up periods. Finally, the current study monitored participants
across a four week follow-up period. The results suggested that CPAP compliance was
associated with a decrease in posttraumatic stress symptoms; however, it is unclear if this
reduction in symptoms would be maintained through continued CPAP utilization. Future
studies should include longer follow-up periods in order to evaluate the stability of the
current findings.
Conclusions
Although few published studies have specifically examined the relationship
between PTSD and obstructive sleep apnea, the available data suggests a strong
association between these two diagnoses. The current study adds to this literature by
demonstrating that successful treatment of OSA is associated with a reduction in PTSD
symptoms over time. Future research should attempt to expand these findings by 1)
attempting to replicate the current results using an experimental methodology; and 2)
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attempt to elucidate the possible mechanisms underlying the relationship between PTSD
and OSA.
The current findings also have important clinical considerations. It appears that
individuals with PTSD are at elevated risk for concurrent OSA and may benefit from
identification and treatment of this physical sleep disorder. It is important for treatment
providers working with individuals with PTSD or OSA to expand their assessment of
sleep dysfunction to include both the evaluation of primary physical sleep disorders as
well as secondary symptoms of a psychiatric diagnosis. Without a more complete
diagnostic understanding of an individual’s sleep dysfunction (i.e., identifying and
treating only physical sleep disorders or only psychiatric symptoms), it is possible that an
individual will continue to experience sleep difficulty with the potential to undermine
treatment for one or both conditions.
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